NCT01046487 2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1 Completed
Clinical Trials
1,081 trialsNCT05814900 2026-03-13
Investigation of Mohs Surgical Margins Using Two Photon Microscopy
University of Rochester
Phase NA Completed
NCT03239145 2026-03-12
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02858869 2026-03-09
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
Emory University
Phase 1 Completed
NCT07427953 2026-03-06
Clinical and Functional Retinal Changes Associated With BRAF/MEK Inhibitor Therapy in Patients With Malignant Melanoma
Institute of Oncology Ljubljana
Completed
NCT06167096 2026-03-05
Effects of Lavender Aromatherapy on Patient Anxiety During Mohs Micrographic Surgery
Case Comprehensive Cancer Center
Phase NA Completed
NCT04335890 2026-03-04
IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma
Hasumi International Research Foundation
Phase 1 Completed
NCT07441538 2026-03-03
Optimizing the Timing for Facial Surgical Dressing Removal
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase NA Completed
NCT07436390 2026-03-02
MAK
Institute of Oncology Ljubljana
Phase NA Completed
NCT02645149 2026-02-27
Match Mel
Melanoma Institute Australia
Phase 2 Completed
NCT03501368 2026-02-27
Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT07434323 2026-02-25
LAPAM
San Gallicano Dermatological Institute IRCCS
Phase NA Completed
NCT07422805 2026-02-24
ctDNA
Institute of Oncology Ljubljana
Phase NA Completed
NCT07431489 2026-02-24
Retinal Structural and Functional Changes in Patients Treated With BRAF/MEK Inhibitors
Institute of Oncology Ljubljana
Phase NA Completed
NCT01659151 2026-02-20
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT04526730 2026-02-20
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT05923060 2026-02-20
Imaging Techniques to Monitor Photosensitizer and sO2 Levels During Photodynamic Therapy of Actinic Keratoses
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02517736 2026-02-17
O-Mel-Sora
University Hospital, Caen
Phase 2 Completed
NCT04552223 2026-02-11
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
University of Miami
Phase 2 Completed
NCT05872854 2026-02-09
RW-HPN-MF-01
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT01625351 2026-02-06
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
Phase 1 Completed
NCT07204704 2026-02-03
EUREKA
University of Utah
Phase NA Completed
NCT07384299 2026-02-03
Impact of Skin Type on Wonud Healing and Scarring Following Facial Skin Surgery
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Completed
NCT03756792 2026-01-29
Assessing Patient Anxiety During Mohs Micrographic Surgery
Wake Forest University Health Sciences
Phase NA Completed
NCT03356470 2026-01-28
Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma
University of Wisconsin, Madison
Completed
NCT02636569 2026-01-21
Topical Chemoprevention of Skin Cancer Biomarkers
University of Alabama at Birmingham
Phase 2 Completed
NCT02862743 2026-01-21
MELCIRC
CHU de Reims
Phase NA Completed
NCT03028948 2026-01-14
Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma
Rutgers, The State University of New Jersey
Phase NA Completed
NCT07334600 2026-01-12
ANDAL-SK
Universitas Sumatera Utara
Phase NA Completed
NCT03873818 2026-01-09
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
M.D. Anderson Cancer Center
Phase 2 Completed
NCT07327164 2026-01-09
Precision Medicine for Neurocutaneous Syndromes in Western China
West China Hospital
Completed
NCT05707286 2026-01-07
ICI-PICK
Indiana University
Completed
NCT05482880 2026-01-06
Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region
Maastricht University Medical Center
Completed
NCT07053852 2026-01-02
Activation of Ameluz With BBL HEROic for the Treatment of Actinic Keratoses and Photodamage
Rochester Dermatologic Surgery
Phase 1 Completed
NCT03405155 2025-12-31
Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery
Thomas Jefferson University
Phase 2 Completed
NCT02917473 2025-12-30
FADEMELA
University Hospital, Tours
Phase NA Completed
NCT03993678 2025-12-30
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.
Swiss Cancer Institute
Phase 1/2 Completed
NCT01970358 2025-12-29
A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Dana-Farber Cancer Institute
Phase 1 Completed
NCT06113081 2025-12-24
FIL_MOGA
Fondazione Italiana Linfomi - ETS
Completed
NCT00799188 2025-12-19
CERTICOEUR
Hospices Civils de Lyon
Phase 3 Completed
NCT01005745 2025-12-19
Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT01701674 2025-12-19
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT03509467 2025-12-19
Using MC1R Genotype to Impact Melanoma Risk Behavior
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT07290959 2025-12-18
Indoor Daylight Photodynamic Therapy is an Effective, First-line Treatment for AK, But Its Feasibility is Limited by the Time Required for the Illumination (2 Hours). Our Objective Was to Evaluate the Efficacy of Idl-PDT With an Illumination Time of 1 Hour Versus 2 Hours in the Treatment of Scalp AK
San Salvatore Hospital of L'Aquila
Phase NA Completed
NCT03534947 2025-12-16
SONIB
Melanoma Institute Australia
Phase 2 Completed
NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
NCT05675709 2025-12-08
Enhancing Skin Cancer Early Detection and Treatment in Primary Care
OHSU Knight Cancer Institute
Phase NA Completed
NCT02639026 2025-11-25
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT01334008 2025-11-24
Study of Circulating Tumoral DNA in Metastatic Choroidal Melanoma
Institut Curie
Phase NA Completed
NCT04223570 2025-11-21
Portable Measurement of Protoporphyrin IX in the Skin
Dartmouth-Hitchcock Medical Center
Completed